Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06), Bloomberg Earnings reports. During the same period in the prior year, the firm earned ($0.62) EPS.
Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $2.73 on Friday. Sunesis Pharmaceuticals has a one year low of $1.82 and a one year high of $4.45. The company has a debt-to-equity ratio of -0.34, a current ratio of 1.84 and a quick ratio of 1.84.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/sunesis-pharmaceuticals-inc-snss-issues-earnings-results-misses-estimates-by-0-06-eps.html.
A number of equities research analysts recently issued reports on SNSS shares. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a report on Thursday, August 24th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 target price on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. ValuEngine cut shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd.
In other news, major shareholder Mpm Oncology Impact Management acquired 25,300 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were purchased at an average cost of $2.59 per share, for a total transaction of $65,527.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Dayton Misfeldt bought 400,000 shares of Sunesis Pharmaceuticals stock in a transaction on Friday, October 27th. The stock was acquired at an average cost of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. Insiders acquired 506,800 shares of company stock worth $1,091,282 over the last quarter. 10.21% of the stock is currently owned by insiders.
An institutional investor recently raised its position in Sunesis Pharmaceuticals stock. Vanguard Group Inc. lifted its position in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 4.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 605,759 shares of the biopharmaceutical company’s stock after buying an additional 23,819 shares during the quarter. Vanguard Group Inc. owned approximately 2.58% of Sunesis Pharmaceuticals worth $1,635,000 at the end of the most recent quarter. 56.43% of the stock is owned by institutional investors.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.